Horizon Discovery Offers Improved Workflow for Cell-line Engineering with CRISPR-Cas9 in Educational Webinar

Share Article

LabRoots will host the webinar June 27, in which attendees will gain a better understanding of the best practices and methods available to rapidly determine genotype.

Laura Carleton, PhD Scientific Liaison and Trainer, Horizon Discovery

CRISPR-Cas9 is a versatile tool to discover more about biological pathway or gene of interest. The simplicity of the CRISPR-Cas9 system has led to an explosion in applications, from single cell genomics to personalized medicine.

After more than 10 years of experience in cell line engineering, the team at Horizon Discovery has optimized all steps of the workflow. This webinar will present some useful tips and tricks that can help minimize the bench time needed to reach your gene-engineering goals. These best practices will increase the confidence in results with thorough validation of your phenotype.

Aside from an introduction to CRISPR-Cas9 genome engineering, in this webinar, which is sponsored by Horizon Discovery, participants will learn the key considerations when embarking on your gene engineering project such as designing reagents, targeting the gene of interest, and validating the resulting clones as well as the benefit of using a secondary model.

Scientific liaison and trainer for Horizon Discovery, Dr. Laura Carleton, will be the speaker for this event. Carlton received her Bachelor of Science from Trinity University in Dublin before earning her doctorate in biochemistry and molecular biology from the National University of Ireland. She has been using and generating cell lines and model systems for eight years.

LabRoots will host this webinar June 27, 2018, beginning at 8 a.m. PDT, 11 a.m. EDT. To learn more about this event, the continuing education credits offered, or to register for free, click here.

About Horizon Discovery Group plc
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon’s platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company’s own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Sorenson
LabRoots, Inc.
+1 (619) 861-0590
Email >
Visit website